Author:
Kurosumi Masafumi,Takatsuka Yuichi,Watanabe Toru,Imoto Shigeru,Inaji Hideo,Tsuda Hitoshi,Akiyama Futoshi,Sakamoto Goi,Ikeda Tadashi,Noguchi Shinzaburo
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference27 articles.
1. Anderson TJ, Dixon JM, Stuart M, Sahmoud T, Miller WR (2002) Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer. Br J Cancer 87:334–338
2. ATAC Trialists’ Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62
3. Beresford MJ, Stott D, Makris A (2007) Assessment of clinical response after two cycles of primary chemotherapy in breast cancer. Breast Cancer Res Treat, 11 July 2007 (E-pub ahead of print)
4. Buzdar AU, Valero V, Theriault RL, Frye D, Green M, Booser D, Guerra L, Sahin A, Ames F, Smith T, Singletary E, Hortobagyi GN (2003) Pathological complete response to chemotherapy is related to hormone receptor status. Breast Cancer Res Treat 82 (Suppl 1):S69, abs 302
5. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676–3685
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献